The easing on restrictions represents a growing acceptance of kava as a natural and safe alternative for managing stress and anxiety.
Showing 25 of 2965
The two companies have developed breakthrough low GI roti canai, roti and chapatti.
Resonance’s FerriSmart is an artificial intelligence based liver-iron-concentration quantification tool.
The Optima device is a customised 3D-printed nylon oral appliance that advances the jaw forward to open the airway and improves the effectiveness of oral appliance therapy.
The company will also present at the 2019 Biotech Showcase in San Francisco.
After four weeks of treatment with PAT-DX1, treated mice showed 93% less brain metastasis than untreated mice.
The deal will enable Starpharma to leverage its treatment product with growing demand in the US for new and non-antibiotic therapies.
The call will discuss the phase IIb randomised double-blind placebo controlled multicentre study.
The IPO funding will go towards accelerating the company’s testing program to demonstrate performance and safety.
A trading halt will remain in place until the start of trading on Tuesday, December 18, or when an announcement is released.
Paradigm is focused on repurposing the drug pentosan polysulfate sodium in its injectable form
The company’s HeraBEAT device is a smartphone-based home fetal heart rate monitoring solution.
Both Ms Zhang and Dr Wu bring commercial and scientific experience and networks in China.
The study provides proof-of-concept for well-tolerated chemotherapy with meaningful survival benefit.
Matthew McDonnell served more than 24 years at KPMG, including 10 years as a partner.
PromarkerD is the world's first commercial test for predicting the onset of diabetic kidney disease.
Uniquely designed patient study which allows the comparison of multiple drugs on the same patient at the same time.
The company is aiming to raise a further $10.5 million from a non-renounceable entitlement offer.
The company’s shares are trading about 10% higher intra-day, at 5.6 cents.
The commercial launch of Fantom Encore solidifies REVA’s technological lead in bioresorbable scaffolds.
The company has developed heart valve technology and has an immunotherapy business.
Cellmid’s consumer health segment generates revenue by selling anti-ageing functional cosmetics and consumer health products.
BARD1 breast cancer test accurately distinguishes malignant breast cancer from benign lesions.
Shares in the drug development company last traded at 73 cents before the halt.
Technegas is inhaled by patients and allows the diagnosis of multiple respiratory diseases via imaging and analytical software